Response: Re: Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non–Small Cell Lung Cancer

Theodore Karrison Michael Maitland Walter Stadler and Mark J. Ratain

首页> 外文期刊>Journal of the National Cancer Institute >Response: Re: Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non–Small Cell Lung Cancer

【24h】

Response: Re: Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non–Small Cell Lung Cancer

机译：回应：Re：使用连续变化的肿瘤大小终点设计II期癌症试验：在非小细胞肺癌中索拉非尼和厄洛替尼的研究中的应用

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of the National Cancer Institute》 |2008年第6期|p.446-446|共1页
作者
Theodore Karrison Michael Maitland Walter Stadler and Mark J. Ratain;
展开▼
作者单位

Affiliations of authors: Department of Health Studies (TK), Department of Medicine (MM, WS, MJR), Cancer Research Center (TK, MM, WS, MJR), and Committee on Clinical Pharmacology and Pharmacogenomics (MM, MJR), University of Chicago, Chicago, IL;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Re: Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non–Small Cell Lung Cancer [J] . David J. Stewart Journal of the National Cancer Institute . 2008,第6期

机译：回复：使用肿瘤大小变化的连续终点进行的II期癌症试验设计：在非小细胞肺癌索拉非尼和厄洛替尼研究中的应用
2. Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non–Small-Cell Lung Cancer [J] . Theodore G. Karrison Michael L. Maitland Walter M. Stadler and Mark J. Ratain Journal of the National Cancer Institute . 2007,第19期

机译：使用肿瘤大小变化的连续终点设计II期癌症试验：在非小细胞肺癌索拉非尼和厄洛替尼研究中的应用
3. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. [J] . Karrison TG, Maitland ML, Stadler WM, Journal of the National Cancer Institute . 2007,第19期

机译：使用肿瘤大小变化的连续终点进行的II期癌症试验设计：应用于索拉非尼和厄洛替尼在非小细胞肺癌中的研究。
4. Clinical studies of SP1049C, a polymer based anthracycline effective against drug resistant tumors. Results of phase II trial and pivotal phase Ⅲ program in upper gastrointestinal cancer indications [C] . Valery Alakhov Controlled Release Society Annual Meeting and Exposition . 2007

机译：SP1049C的临床研究，一种基于聚合物的蒽环类药物可有效抵抗耐药性肿瘤。上消化道癌适应症的II期试验和关键性III期试验结果
5. A Study of Erlotinib Monotherapy and in Combination with Pembrolizumab in Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer [D] . Liu, Qiong. 2021

机译：Erlotinib单疗法和蛋白质在先前未处理阶段I-IIIA非小细胞肺癌中的研究
6. Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study [O] . Martin Reck, Anders Mellemgaard, Silvia Novello, 2018

机译：nintedanib联合多西他赛治疗的患者的非小细胞肺癌肿瘤大小的变化：来自LUME-Lung 1期III期研究的分析
7. Re: Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non-Small Cell Lung Cancer [O] . D. J. Stewart 2008

机译：Re：使用肿瘤大小的连续变化的连续终点设计II期癌症试验：在非小细胞肺癌中的索拉非尼和厄洛替尼研究中的应用

Response: Re: Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non–Small Cell Lung Cancer

著录项

相似文献

相关主题

期刊订阅